Contract analysis

I. Executive Summary This memorandum analyzes the contract manufacturing agreement (the "CMA" or the "Agreement") between Penterra Biopharma International DAC ("PBI") and Penterra Manufacturing Ireland Ltd. ("PMI") for compliance with the arm's-length standard under the cost-plus method prescribed by Treasury Regulation § 1.482-3(d). This analysis is undertaken in connection with the ongoing examination by the Intern

II. Background A. Parties to the Agreement The CMA is entered into between two Irish entities within the PPC group: PBI, as the buyer and commercial principal, and PMI, as the contract manufacturer. The relevant characteristics of each entity are summarized below. Penterra Biopharma International DAC ("PBI"). PBI is a designated activity company organized under the laws of Ireland, with its registered office at 4th F

III. Applicable Legal and Regulatory Framework A. IRC § 482 — General Authority

Section 482 of the Internal Revenue Code grants the Secretary of the Treasury (and by delegation, the Commissioner of Internal Revenue) broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distributio

IV. Functional Analysis of PMI A thorough functional analysis of PMI — encompassing the functions it performs, the assets it employs, and the risks it assumes — is essential to its proper characterization under the transfer pricing regulations and to the determination of whether the cost + 8% markup produces an arm's-length result. The following analysis demonstrates that PMI is properly characterized as a limited-ri

V. Analysis of the Cost + 8% Markup A. Description of the Cost Base The cost base to which the 8% markup is applied under the CMA is composed of the following categories of costs incurred by PMI in the performance of its manufacturing functions: Direct Costs. PMI's direct costs include raw materials, active pharmaceutical ingredients ("APIs"), direct manufacturing labor, and manufacturing overhead directly attributab

VI. Relevance to IRS Examination Defense A. Supporting PBI's Economic Substance The PMI contract manufacturing arrangement is a critical piece of evidence supporting PBI's characterization as a full-fledged IP owner and commercial principal with genuine economic substance in Ireland. The IRS examination has focused significant attention on whether PBI possesses the substance, personnel, and decision-making authority

VII. Potential Vulnerabilities and Risk Assessment While we believe that the cost + 8% markup is defensible under the arm's-length standard, we identify the following potential vulnerabilities and associated risk factors that should be addressed in preparing the examination defense. A. Cost Base Definition There is a risk that the IRS could challenge the composition of PMI's cost base, arguing that certain cost items

VIII. Recommendations Based on the foregoing analysis, we make the following recommendations:

1. Formal Benchmarking Study. We recommend that Whitmore Valuation Group LLC include a formal benchmarking study of PMI's cost + 8% markup in their overall economic analysis supporting PPC's examination defense. Although the IRS has not directly challenged the PMI manufacturing arrangement in the NOPA, proactive documentation of the arm's-length character of the PMI markup strengthens the overall defense posture and

2. Contemporaneous Documentation Review. We recommend that the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Martin Ogilvy, Engagement Partner; Susan Lam, Transfer Pricing Partner) for taxable years 2017–2020 be reviewed to ensure that it adequately describes the PMI arrangement, the cost base composition, the functional analysis of PMI, and the arm's-length justification for

3. IDR Response Strategy. In responding to Information Document Requests from the IRS (47 IDRs issued between June 2022 and September 2023), we recommend that the PMI arrangement be presented as evidence of PBI's substantive control over the non-Americas supply chain. Specifically, IDR responses should highlight PBI's management of the PMI manufacturing relationship — including purchase order issuance, quality oversi

4. Coordination with Irish Tax Advisors. We recommend coordination with Thornbury & Keogh (Ciarán Thornbury, Lead Partner; 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland) to ensure consistency between the U.S. and Irish transfer pricing positions for the PMI arrangement. Any inconsistency between the U.S. and Irish positions could undermine the credibility of PPC's transfer pricing framework and could create expo

5. Formal Protest and Appeals. For the formal Protest to be filed with the IRS (deadline extended to December 22, 2023) and for any subsequent Appeals proceedings, we recommend that the PMI arrangement